Endometrial stromal sarcoma of the uterus: analysis of 25 patients.
OBJECTIVE
To analyze the prognostic factors in endometrial stromal sarcoma (ESS).


METHODS
Prognostic factors and adjuvant treatment of endometrial stromal sarcoma in 25 patients were evaluated retrospectively.


RESULTS
The mean age of the group was 43. In 58% of the patients, the presenting sign was vaginal bleeding. The median total survival was 55 months while the disease free survival (DFS) was 49 months. Disease recurred in eight patients, in three of whom tumors were confined to the pelvis. Seventeen patients were alive without disease. Four patients died because of the disease. The 5-year survival rate for patients with low-grade (LGESS) disease was 92%, and 85% in high-grade (HGESS) disease.


CONCLUSIONS
In multivariate analyzes, tumor grading was the only prognostic factor in endometrial stromal sarcoma (P=0.0026).
Haberal
Ali
A
Department of Gynecologic Oncology, SSK Ankara Maternity Hospital, Etlik TR06010, Ankara, Turkey.
Kayikçioğlu
Fulya
F
Boran
Nurettin
N
Calişkan
Eray
E
Ozgül
Nejat
N
Köse
M Faruk
MF
D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy